Hansen Ho, PharmD
Oncology & Infusion Supervisor
COO
Chancellor/EVC/FAS

Awards

Show all (2) Hide

• Val Louie Award, UCSF Department of Pharmaceutical Services
• Gary Rifkand Spring Research Conference, UCSF School of Pharmacy, Department of Clinical Pharmacy

Education & Training

Show all (4) Hide

• B.S. Biochemistry and Molecular Biology University of California, Davis
• PGY2 Oncology Residency Pharmacy University of California, San Francisco
• PharmD Pharmacy University of California, San Francisco
• PGY1 Residency Pharmacy University of Southern California

Interests

Show all (3) Hide

• immunotherapy
• colorectal cancer
• chemotherapy desensitization

Publications (2)

Top publication keywords:
Antineoplastic Combined Chemotherapy ProtocolsUrotheliumTaxoidsBridged-Ring CompoundsPromoter Regions, GeneticTrastuzumabBreast NeoplasmsDisease ProgressionCarcinomaAntibodies, Monoclonal, HumanizedMutationUrologic NeoplasmsBiomarkers, TumorDNA Mutational AnalysisTelomerase

• TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor.
  Journal for immunotherapy of cancer 2021 de Kouchkovsky I, Zhang L, Philip EJ, Wright F, Kim DM, Natesan D, Kwon D, Ho H, Ho S, Chan E, Porten SP, Wong AC, Desai A, Huang FW, Chou J, Oh DY, Pruthi RS, Fong L, Small EJ, Friedlander TW, …
• Combination pertuzumab, trastuzumab, and taxane for metastatic breast cancer after first progression: a single institution's experience.
  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2015 Dao BD, Ho H, Quintal LN